SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)

• Status: Completed
• Trial end date: 2006-05-17
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Patient is currently a nonsmoker and has been a nonsmoker for at least 1 year

• Patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis

Exclusion Criteria:

• Patient has been treated in an emergency room for asthma within 4 weeks or has been hospitalized for asthma within 3 months prior to visit 1

• Patient with severe asthma, upper respiratory infection, sinusitis, infectious rhinitis, non-allergic rhinitis

• Patient has any active, acute, or chronic pulmonary disorder that is documented by history, physical examination